Jul. 1 at 2:11 PM
$SER
BTIG initiated coverage on Serina Therapeutics (NYSE:SER) with a Buy rating and a price target of
$8.00. The stock currently trades at
$1.94 with a market cap of
$29.1 million, representing substantial upside potential to the analyst target. According to most undervalued stocks list
BTIG said the upcoming readouts for SER-252 in late 2026 and the first half of 2027 represent the next major catalysts for the stock. The firm said SER-252 could become standard of care in 250,000 later staged Parkinson’s disease patients.
In August 2025, Serina held an FDA pre-IND meeting and secured alignment on a 505(b)(2) NDA regulatory pathway. This agreement allows the company to use existing data showing apomorphine is relatively safe and active in Parkinson’s disease patients.
